Evidence map›Paper›PMID 39996761›Full record

ArticleCells2025

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells.

Lucia Kucerova, Adriana Fekiacova, Natalia Udvorkova, Pavlina Malcharkova, Viktoria Blahova, Silvia Jochova, Katarina Kalavska, Zuzana Cierna, Michal Mego

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lucia KucerovaTranslational Research Unit, 2nd Oncology Clinic of the Medical Faculty, Comenius University, and the National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.ORCID 0000-0002-6407-6659
Adriana FekiacovaTranslational Research Unit, 2nd Oncology Clinic of the Medical Faculty, Comenius University, and the National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.
Natalia UdvorkovaTranslational Research Unit, 2nd Oncology Clinic of the Medical Faculty, Comenius University, and the National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.ORCID 0009-0000-1568-3471
Pavlina MalcharkovaTranslational Research Unit, 2nd Oncology Clinic of the Medical Faculty, Comenius University, and the National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.
Viktoria BlahovaTranslational Research Unit, 2nd Oncology Clinic of the Medical Faculty, Comenius University, and the National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.
Silvia JochovaCancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.ORCID 0000-0003-4537-2062
Katarina KalavskaTranslational Research Unit, 2nd Oncology Clinic of the Medical Faculty, Comenius University, and the National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.
Zuzana CiernaDepartment of Pathology, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia.
Michal MegoTranslational Research Unit, 2nd Oncology Clinic of the Medical Faculty, Comenius University, and the National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovakia.

Funding

Scientific Grant Agency of the Ministry of Education and Science of the Slovak Republic VEGA 02/0124/21Slovak Research and Development Agency APVV-20-0158
6 · The paper itself

Abstract

Patients with treatment-refractory/relapsing germ cell tumors (GCTs) have a dismal prognosis due to a lack of any effective therapy. Moreover, the efficacy of newly approved targeted therapies remains unexplored for cisplatin-resistant GCTs. Previously, it was demonstrated that folate receptor α (FRα) is overexpressed in many tumor types and efficiently targeted by the antibody-drug conjugate (ADC) mirvetuximab soravtansine (MIRV) in cisplatin-resistant cancers. We hypothesized that FRα represents an attractive target for treating treatment-refractory GCTs. We determined the expression of the

Indexed as

Antibodies, Monoclonal, HumanizedBystander EffectCisplatinDrug Resistance, NeoplasmImmunoconjugatesMaytansineNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAnimalsApoptosisCell Line, TumorFolate Receptor 1HumansMaleMiceMice, NudeAntibodies, Monoclonal, HumanizedCisplatinFolate Receptor 1FOLR1 protein, humanImmunoconjugatesMaytansinemirvetuximab soravtansineantibody–drug conjugatebystander effectchemoresistancecisplatingerm cell tumorsmirvetuximab soravtansine

Identifiers

PMID39996761
PMCPMC11853988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.